Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Ipsen S.A. ADR (IPSEY)

Ipsen S.A. ADR (IPSEY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) Newswire.ca - Mon Nov 13, 2023

/CNW/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and...

IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. Business Wire - Fri Jan 27, 2023

Regulatory News:

OTC.VN : 0.290 (-9.38%)
IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI Business Wire - Fri Jan 20, 2023

Regulatory News:

OTC.VN : 0.290 (-9.38%)
IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)
Why These Two Biotech Stocks Blasted Higher This Week Motley Fool - Fri Jan 13, 2023

There's nothing like a big-premium buyout to send a company's share price to the moon.

AZN : 77.13 (-0.27%)
IPSEY : 30.0700 (-0.82%)
CINC : 29.06 (-0.48%)
ALBO : 44.15 (-0.23%)
SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc. PR Newswire - Mon Jan 9, 2023

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc....

IPSEY : 30.0700 (-0.82%)
ALBO : 44.15 (-0.23%)
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday Motley Fool - Mon Jan 9, 2023

The market is moving higher, and these small companies are helping.

COMP : 3.63 (+0.83%)
$NASX : 18,403.74 (+0.28%)
DCT : 18.99 (unch)
ALBO : 44.15 (-0.23%)
IPSEY : 30.0700 (-0.82%)
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases Business Wire - Mon Jan 9, 2023

Regulatory News:

OTC.VN : 0.290 (-9.38%)
ALBO : 44.15 (-0.23%)
IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva Business Wire - Fri Dec 23, 2022

Regulatory News:

OTC.VN : 0.290 (-9.38%)
IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy Business Wire - Thu Dec 8, 2022

Regulatory News:

OTC.VN : 0.290 (-9.38%)
IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Business Wire - Wed Nov 9, 2022

Regulatory News:

OTC.VN : 0.290 (-9.38%)
IPN : 34.71 (-0.54%)
IPSEY : 30.0700 (-0.82%)

Barchart Exclusives

3 Warren Buffett Dividend Stocks to Buy on Every Dip Barchart - Mon Jul 8, 7:36PM CDT
Warren Buffett's top dividend stocks offer a unique combination of stability, growth, and income, making them attractive buys on every dip. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot